Siemens and Biogen cooperate
Siemens Healthineers and Biogen announce agreement to jointly develop new MRI tools for multiple sclerosis
Siemens Healthineers and Biogen announced that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key markers of multiple sclerosis (MS) disease activity and progression. Siemens Healthineers aims to enable healthcare providers to meet their current challenges and excel in their respective environments. To execute this strategy in the field of neurology, Siemens Healthineers will cooperate with Biogen and contributes its strength in medical imaging.
"By bringing together the shared expertise of both Siemens Healthineers and Biogen in imaging and neurology, respectively, we seek to develop new measurement tools that meet the particular technical challenges of MS," says Dr. Christoph Zindel, Senior Vice President of Magnetic Resonance Imaging at Siemens Healthineers. "Our shared goal is to create a solution that can be integrated into the existing radiology workflow, so it can become a seamless part of routine care – delivering new and valuable information to treating neurologists, without increasing the cost or burden on the healthcare system."
MRI is routinely used to support physicians in diagnosing MS, measuring disease activity and monitoring response to therapy. Clinicians qualitatively evaluate MRIs by comparing the current MRI to the previous MRI. Numerous studies have demonstrated that quantitative MRI measures may provide additional information about disease prognosis and therapeutic effect, but today quantitative measurement techniques with the precision and sensitivity required for MS are typically only available in the research setting. With the development and validation of automated MRI applications to quantify key markers of MS, including new T2 lesions and brain atrophy, patients could benefit from the availability of enhanced data at the point of care.
"Biogen believes that the availability of high-quality, standardized data at the point of care can lead to a deeper understanding of MS, more informed treatment decisions and, ultimately, improved patient outcomes" says Richard Rudick, MD, Vice President Development Sciences, Biogen. "We also recognize that the ability to generate research-quality data in the course of routine clinical practice can unlock the potential of the health care system to move towards precision medicine."
Other news from the department business & finance
Most read news
Last viewed contents
New financing round at oncgnostics GmbH close
Bioactive novel compounds from endangered tropical plant species
XCAM is UK’s “Most Innovative” Life Science Company
Celsius® Shippable Storage Module | Refrigerated containers | Sartorius
Powerhouses in the cell dismantled Flemish technology at VIB - Ghent University creates revolution in protein research
Mobile phone app accurately detects COVID-19 infection in people’s voices with the help of artificial intelligence - The AI model used in this research is more accurate than lateral flow/rapid antigen tests
Harnessing Mutations: A Breakthrough in Fruit Fly Genetics - A game-changing technique, TF-High-Evolutionary (TF-HighEvo), allows large-scale assessment of de-novo mutations in multicellular organisms
